A5056422629- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Sarcoidosis and Beryllium Toxicity Research
- COVID-19 Clinical Research Studies
- Medical Imaging and Pathology Studies
- SARS-CoV-2 and COVID-19 Research
- Pulmonary Hypertension Research and Treatments
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- COVID-19 and Mental Health
- COVID-19 and healthcare impacts
- Intensive Care Unit Cognitive Disorders
- Occupational and environmental lung diseases
- Long-Term Effects of COVID-19
- Respiratory Support and Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- COVID-19 Impact on Reproduction
- Thermal Regulation in Medicine
- Eosinophilic Disorders and Syndromes
- Inflammatory Myopathies and Dermatomyositis
University of Cincinnati Medical Center
2024
University of Calgary
2022-2023
University of British Columbia
2021-2023
Kingston General Hospital
2022-2023
BC Centre for Disease Control
2022-2023
Sinai Hospital
2022-2023
University of Toronto
2022-2023
Surrey Memorial Hospital
2022-2023
Sunnybrook Health Science Centre
2022-2023
Health Sciences Centre
2022-2023
Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by progressive physiological, symptomatic and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain.Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015 2020. was defined as a relative forced vital capacity (FVC) decline ≥10%, death, transplantation or any two of: FVC ≥5% <10%, worsening respiratory symptoms fibrosis on computed tomography...
Abstract Rationale Acute respiratory distress syndrome (ARDS) is a life-threatening critical care commonly associated with infections such as COVID-19, influenza, and bacterial pneumonia. Ongoing research aims to improve our understanding of ARDS, including its molecular mechanisms, individualized treatment options, potential interventions reduce inflammation promote lung repair. Objective To map compare metabolic phenotypes different infectious causes ARDS better understand the pathways...
Objectives: To determine whether angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors are associated with improved outcomes in hospitalized patients COVID-19 according to sex and report sex-related differences renin-angiotensin system (RAS) components. Design: Prospective observational cohort study comparing the effects of ARB ACE versus no ARBs males females. Severe acute respiratory syndrome coronavirus 2 downregulates ACE-2, potentially increasing II (a...
Omicron is the current predominant variant of concern SARS-CoV-2. We hypothesized that vaccination alters outcomes patients hospitalized with COVID-19 during wave and these have different characteristics than in previous waves.This a substudy Host Response Mediators Coronavirus (COVID-19) Infection (ARBs CORONA I) trial, which included adults admitted to hospital acute up July 2022 from 9 hospitals British Columbia, Ontario Quebec. excluded emergency department visits without admission,...
The lung is an understudied site of HIV persistence. We isolated 898 subgenomic proviral sequences ( nef ) by single-genome approaches from blood and nine individuals on long-term suppressive antiretroviral therapy (ART), characterized genetic diversity compartmentalization using formal tests. Consistent with clonal expansion as a driver persistence, identical comprised between 8% to 86% within-host datasets, though their location (blood vs. lung) followed no consistent pattern. majority...
<h3>Background:</h3> There have been multiple waves in the COVID-19 pandemic many countries. We sought to compare mortality and respiratory, cardiovascular renal dysfunction between 3 Canadian provinces. <h3>Methods:</h3> conducted a substudy of ARBs CORONA I study, multicentre pragmatic observational cohort study that examined association pre-existing use angiotensin receptor blockers with outcomes adults admitted hospital acute up April 2021 from 9 community teaching hospitals provinces...
Abstract Background and objective Rheumatoid arthritis (RA) is a frequent cause of interstitial lung disease (ILD); however, the impact rheumatoid factor anti‐citrullinated peptide antibody seropositivity in ILD without connective tissue (CTD) unclear. We examined association with progression, mortality response to immunosuppression non‐CTD ILD. Methods A total 1570 patients (with idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, pneumonia autoimmune features or unclassifiable...
Background Fibrotic interstitial lung disease (ILD) is frequently associated with abnormal oxygenation; however, little known about the accuracy of oxygen saturation by pulse oximetry (SpO 2 ) compared arterial blood gas (ABG) (SaO ), factors that influence partial pressure carbon dioxide (PaCO and impact PaCO on outcomes in patients fibrotic ILD. Study design methods Patients ILD enrolled a large prospective registry room air ABG were included. Prespecified analyses included testing...
Abstract The lung is an understudied site of HIV persistence. We isolated 882 subgenomic proviral sequences by single-genome approaches from blood and nine individuals on long-term suppressive antiretroviral therapy (ART), characterized genetic diversity compartmentalization using formal tests. Consistent with clonal expansion as a driver persistence, identical comprised between 9% to 86% within-host datasets, though their location (blood vs. lung) followed no consistent pattern. majority...
Rationale: Mycophenolate (MMF) and azathioprine (AZA) are two immunosuppressive medications commonly used in patients with fibrotic interstitial lung diseases (ILDs).We sought to determine the prescribing patterns tolerability of MMF AZA using a real-world cohort ILD.Methods: Patients connective tissue disease ILD (CTD-ILD), hypersensitivity pneumonitis (HP), unclassifiable were identified from 8-center prospective CAnadian REgistry for Pulmonary Fibrosis (CARE-PF).Medication data obtained...